Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

In its updated report, Hims & Hers Health, Inc. (NYSE:HIMS) said revenues increased by 73 percent to $544.8 million from $315 ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

US stocks end lower after data show higher prices and lower employment. Investors also weigh earnings and Trump tariff threats.

Palantir rose after earnings blew past Wall Street estimates, while shares of Vertex Pharmaceuticals and Hims & Hers ...

Gibbs Mura encourages investors to contact us about their legal rights and options in the Hims & Hers Health, Inc. (NYSE: HIMS) Securities Class Action Lawsuit . What Should Hims & Hers Investors Do?

Hims & Hers Health posted an increase in profit and revenue for the second quarter on growth in subscribers using personalized treatment plans. The telehealth-consultation platform on Monday posted a ...